Etanercept
- PDF / 169,316 Bytes
- 1 Pages / 595.245 x 841.846 pts (A4) Page_size
- 78 Downloads / 173 Views
1 S
Ileal Crohn’s disease: case report A 39-year-old man developed ileal Crohn’s disease during treatment with etanercept for psoriatic ankylosing spondylitis. The man, who had HLA-B27 negative psoriatic ankylosing spondylitis, had been receiving etanercept since March 2017 [dosage and route not stated]. In May 2019, he developed subocclusive symptoms. Faecal calprotectin showed elevated level at 1200. A colonoscopy revealed stenosis and ulceration at the level of the ileocaecal valve. Biopsies revealed chronic nonspecific inflammatory infiltrate. A magnetic resonance enterography revealed two significant ileal stenosis of 3cm and 7cm, with proximal dilation and acute inflammatory activity consistent with ileal Crohn’s disease. The man’s treatment was started with unspecified corticosteroids with improvement in his digestive symptoms. Additionally, his etanercept therapy was changed to infliximab. Thereafter, his digestive and rheumatologic disease were adequately controlled. Cortazar EV, et al. Ileal Crohn's disease in a patient being treated with etanercept. [Spanish]. Revista Espanola de Enfermedades Digestivas 112: 85, No. 1, 2020. 803498400 Available from: URL: http://doi.org/10.17235/REED.2019.6554/2019 [Spanish; summarised from a translation]
0114-9954/20/1819-0001/$14.95 Adis © 2020 Springer Nature Switzerland AG. All rights reserved
Reactions 29 Aug 2020 No. 1819
Data Loading...
